The purpose of this study is to evaluate the efficacy of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
Age: 18 years - 66+
Gender: All
We've found 6 total results for "Hematologic Neoplasms".
The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).
Age: 18 years - 66+
Gender: All
The purpose of this study is to characterize the safety of Talquetamab and to determine the recommended Phase 2 dose(s) (RP2Ds) and dosing schedule assessed to be safe for Talquetamab (Part 1 [Dose Escalation]) and to further characterize the safety of Talquetamab a...
Age: 18 years - 66+
Gender: All
This trial will evaluate magrolimab, a monoclonal antibody which is designed to block a protein called CD47, which is widely expressed on human cancer cells. Blocking CD47 with magrolimab may enable the body's immune system to find and destroy the cancer cells. In thi...
Age: 18 years - 66+
Gender: All
The purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for Teclistamab and to characterize the safety and tolerability of Teclistamab at the RP2Ds.
Age: 18 years - 66+
Gender: All
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
- Lymphoma
- Leukemia
- Multiple Myeloma
- Neoplasms
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Hematologic Neoplasms
- Leukemia, Myeloid, Acute
- Anemia, Aplastic
- Congenital Abnormalities
- Autoimmune Diseases
- Disease
Age: Birth - 66+
Gender: All